NuPathe, Inc. (PATH) was a big mover last session, as its shares surged over 47% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the healthcare stock, as it is now up nearly 94% in the past one-month time frame.
In the last 30 days, the company has seen one negative estimate revision and its Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
NuPathe currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Dov Gertzulin's DG Capital is having a strong year. According to a copy of the hedge fund's letter to investors of its DG Value Partners Class C strategy, the fund is up 36.4% of the year to the end of June, after a performance of 12.8% in the second quarter. The Class C strategy is Read More
Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals plc (JAZZ) and Questcor Pharmaceuticals, Inc. (QCOR). All three companies carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>